{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:08:08Z","timestamp":1768572488673,"version":"3.49.0"},"posted":{"date-parts":[[2025,9,5]]},"group-title":"Neurology","reference-count":23,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cerebral amyloid angiopathy (CAA) remains diagnostically challenging, particularly in asymptomatic individuals. While CAA often co-exists with Alzheimer\u2019s disease (AD), it may even have a direct impact on AD pathophysiology and the cognitive decline within the clinical course of AD. While fluid biomarkers are well-established for AD pathology, reliable markers to improve the characterization of CAA are lacking.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed two subsets of participants from the Alzheimer\u2019s Disease Neuroimaging Initiative: one with available T2*-weighted gradient echo magnetic resonance imaging (MRI) (n=21) and another with postmortem neuropathological data (n=24), all with available plasma biomarkers from a 145-analyte multiplex immunoassay panel. We defined CAA as two or more lobar microbleeds in MRI or moderate to severe neocortical amyloid angiopathy in neuropathological examination. Plasma analytes were assessed twice per subject, one year apart, with the earlier sample obtained up to 6.6 years prior to either the first MRI or neuropathological examination. Non-parametric correlation and receiver operating characteristic curves were mainly reported.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In both cohorts, various markers related to inflammation, lipid metabolism, and cell adhesion were associated with CAA proxy measures. Specifically, both increased (Osteopontin, VCAM-1) and decreased (vitronectin or endothelial growth factor) biomarker levels were associated with MBs, while increased apolipoproteins (ApoAII, ApoCI and ApoCIII, ApoE and clusterin) and decreased AXL were associated with CAA severity in neuropathology. Ratios between inversely associated markers enhanced correlation strength and discriminated CAA status.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Several candidate plasma biomarkers of CAA were identified in individuals with either MRI or neuropathological indicators of CAA.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.09.03.25334994","type":"posted-content","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T22:46:12Z","timestamp":1757112372000},"source":"Crossref","is-referenced-by-count":0,"title":["An explorative analysis of plasma biomarkers associated with cerebral amyloid angiopathy"],"prefix":"10.64898","author":[{"given":"Ersin","family":"Ers\u00f6zl\u00fc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Preis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orkan","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Gref","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"von Droste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Hellmann-Regen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025090914451013000_2025.09.03.25334994v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12366"},{"key":"2025090914451013000_2025.09.03.25334994v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120866"},{"key":"2025090914451013000_2025.09.03.25334994v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-005-1064-y"},{"key":"2025090914451013000_2025.09.03.25334994v1.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2008.00133.x"},{"key":"2025090914451013000_2025.09.03.25334994v1.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.4.537"},{"key":"2025090914451013000_2025.09.03.25334994v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00208-3"},{"key":"2025090914451013000_2025.09.03.25334994v1.7","doi-asserted-by":"crossref","first-page":"e209386","DOI":"10.1212\/WNL.0000000000209386","article-title":"Boston criteria v2.0 for cerebral amyloid angiopathy without hemorrhage: An MRI-neuropathologic validation study","volume":"102","year":"2024","journal-title":"Neurology"},{"key":"2025090914451013000_2025.09.03.25334994v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30440-3"},{"key":"2025090914451013000_2025.09.03.25334994v1.9","first-page":"100010","article-title":"Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review","volume":"2","year":"2021","journal-title":"Cereb. Circ. Cogn. Behav"},{"key":"2025090914451013000_2025.09.03.25334994v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"2025090914451013000_2025.09.03.25334994v1.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21610"},{"key":"2025090914451013000_2025.09.03.25334994v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.10.007"},{"key":"2025090914451013000_2025.09.03.25334994v1.13","doi-asserted-by":"publisher","DOI":"10.1159\/000441919"},{"key":"2025090914451013000_2025.09.03.25334994v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2003.08.007"},{"key":"2025090914451013000_2025.09.03.25334994v1.15","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y"},{"key":"2025090914451013000_2025.09.03.25334994v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-9961(02)00019-0"},{"key":"2025090914451013000_2025.09.03.25334994v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83601-6"},{"key":"2025090914451013000_2025.09.03.25334994v1.18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bpa.12721","article-title":"Osteopontin and phospho-SMAD2\/3 are associated with calcification of vessels in D-CAA, an hereditary cerebral amyloid angiopathy","volume":"29","year":"2019","journal-title":"Brain Pathol"},{"key":"2025090914451013000_2025.09.03.25334994v1.19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00164"},{"key":"2025090914451013000_2025.09.03.25334994v1.20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40478-019-0662-1","article-title":"Apolipoprotein E and clusterin inhibit the early phase of amyloid-\u03b2 aggregation in an in vitro model of cerebral amyloid angiopathy","volume":"7","year":"2019","journal-title":"Acta Neuropathol. Commun"},{"key":"2025090914451013000_2025.09.03.25334994v1.21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","article-title":"Microglia use TAM receptors to detect and engulf amyloid \u03b2 plaques","volume":"22","year":"2021","journal-title":"Nat. Immunol"},{"key":"2025090914451013000_2025.09.03.25334994v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0548-1"},{"key":"2025090914451013000_2025.09.03.25334994v1.23","doi-asserted-by":"crossref","unstructured":"Cummings J , Gold M , Mintun M , Irizarry M , von Eschenbach A , Hendrix S , Berry D , Sampaio C , Sink K , Landen J , et al. Key Considerations for Combination Therapy in Alzheimer\u2019s Clinical Trials: Perspectives from an Expert Advisory Board Convened by the Alzheimer\u2019s Drug Discovery Foundation [Internet]. Available from: http:\/\/dx.doi.org\/10.1016\/j.tjpad.2024.100001","DOI":"10.1016\/j.tjpad.2024.100001"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.03.25334994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:45:00Z","timestamp":1768509900000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.09.03.25334994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1101\/2025.09.03.25334994","relation":{},"subject":[],"published":{"date-parts":[[2025,9,5]]},"subtype":"preprint"}}